Tafasitamab plus lenalidomide for relapsed large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old.
- Have a confirmed diagnosis of relapsed or refractory DLBCL and meet one of the specified DLBCL-related lymphoma subtypes.
- Have had 1 to 3 prior treatment regimens for DLBCL, and at least one treatment must target CD20 (a marker on B-cells).
- Be able to meet required bloodwork rules at screening (labs will be checked before starting).
- If you can become pregnant or father a child, agree to reliable birth-control measures during the study and understand pregnancy-safety requirements.
- Be willing to take “blood clot prevention” medicine if your doctor recommends it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
This study looks at how well a combination of two drugs, tafasitamab and lenalidomide, works for people with a type of lymphoma (DLBCL) that has come back or hasn't responded to treatment. After the combination, patients continue with tafasitamab alone. This is for patients who cannot have a stem cell transplant.
This study looks back at medical records of people with relapsed or refractory diffuse large B-cell lymphoma who received a combination of two drugs (tafasitamab and lenalidomide) through a special access program. The goal is to learn how well the treatment worked and what side effects occurred.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.